Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

KRIT1 Antikörper (N-Term)

KRIT1 Reaktivität: Human WB, IF Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN616004
  • Target Alle KRIT1 Antikörper anzeigen
    KRIT1 (KRIT1, Ankyrin Repeat Containing (KRIT1))
    Bindungsspezifität
    • 15
    • 6
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    AA 1-736, N-Term
    Reaktivität
    • 24
    • 20
    • 5
    Human
    Wirt
    • 35
    • 4
    Kaninchen
    Klonalität
    • 35
    • 4
    Polyklonal
    Konjugat
    • 16
    • 3
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser KRIT1 Antikörper ist unkonjugiert
    Applikation
    • 32
    • 17
    • 13
    • 13
    • 3
    • 3
    • 3
    • 1
    • 1
    Western Blotting (WB), Immunofluorescence (IF)
    Spezifität
    This antibody is anti-His depleated. It detects KRIT1 / CCM1.
    Kreuzreaktivität (Details)
    Species reactivity (tested):Human.
    Aufreinigung
    Protein A Chromatography
    Immunogen
    Highly pure (>95%) recombinant Human CCM-1 (Met1-Ser736) derived from E. coli fused to a C-teminal His-tag (6 x His) (Cat.-No AR26002PU-N)
    Isotyp
    IgG
    Top Product
    Discover our top product KRIT1 Primärantikörper
  • Applikationshinweise
    Optimal working dilution should be determined by the investigator.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Rekonstitution
    Restore in sterile water to a concentration of 0.1-1.0 mg/mL. Centrifuge vial prior to opening.
    Buffer
    5 mM PBS, pH 7.2
    Handhabung
    Avoid repeated freezing and thawing.
    Lagerung
    4 °C/-20 °C
    Informationen zur Lagerung
    Prior to reconstitution store at 2-8 °C. Following reconstitution store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
  • Target
    KRIT1 (KRIT1, Ankyrin Repeat Containing (KRIT1))
    Andere Bezeichnung
    KRIT1 / CCM1 (KRIT1 Produkte)
    Hintergrund
    Cerebral Cavernous Malformations (CCM) are frequent vascular abnormalities caused by mutations in one of the CCM genes. CCM-1 (also known as KRIT1) stabilizes endothelial junctions and is essential for vascular morphogenesis in mouse embryos. However, cellular functions of CCM-1 during the early steps of the CCM pathogenesis remain unknown. It was shown that CCM-1 represents an antiangiogenic protein to keep the human endothelium quiescent. CCM-1 inhibits endothelial proliferation, apoptosis, migration, lumen formation, and sprouting angiogenesis in primary human endothelial cells. CCM-1 strongly induces DLL4-NOTCH signaling, which promotes AKT phosphorylation but reduces phosphorylation of the mitogen-activated protein kinase ERK. Consistently, blocking of NOTCH activity alleviates CCM-1 effects. ERK phosphorylation is increased in human CCM lesions. Transplantation of CCM-1-silenced human endothelial cells into SCID mice recapitulates hallmarks of the CCM pathology and serves as a unique CCM model system.Synonyms: Krev interaction trapped 1
    Gen-ID
    889
    NCBI Accession
    NP_004903
    UniProt
    O00522
    Pathways
    Cell RedoxHomeostasis
Sie sind hier:
Kundenservice